Polyrizon Ltd. Advances Intranasal Naloxone Hydrogel Program
Ticker: PLRZ · Form: 6-K · Filed: Dec 11, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-development, medical-devices, press-release
TL;DR
Polyrizon's naloxone hydrogel shows good permeation, moving their overdose treatment closer to reality.
AI Summary
Polyrizon Ltd. announced on December 11, 2025, promising permeation kinetics for its intranasal naloxone hydrogel program. This development supports the advancement of their drug delivery system, which aims to provide a rapid and effective method for administering naloxone.
Why It Matters
This advancement could lead to a more effective and accessible treatment for opioid overdose, potentially saving lives by enabling faster naloxone administration.
Risk Assessment
Risk Level: medium — The filing reports on promising early-stage results, but clinical and regulatory success is not guaranteed.
Key Players & Entities
- Polyrizon Ltd. (company) — Registrant
- December 11, 2025 (date) — Date of press release
- Naloxone Hydrogel Program (program) — Key development area
FAQ
What specific permeation kinetics were announced by Polyrizon Ltd.?
The filing states that Polyrizon announced 'promising permeation kinetics' but does not provide specific numerical data in this report.
What is the primary purpose of Polyrizon's intranasal naloxone hydrogel program?
The program is focused on developing an intranasal delivery system for naloxone, likely for the treatment of opioid overdose.
When was the press release regarding the permeation kinetics issued?
The press release was issued on December 11, 2025.
Under which SEC form does Polyrizon Ltd. typically file annual reports?
Polyrizon Ltd. indicates it files annual reports under cover of Form 20-F.
What is Polyrizon Ltd.'s principal executive office address in Israel?
Polyrizon Ltd.'s principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 14.3 · Accepted 2025-12-11 08:21:36
Filing Documents
- ea0269293-6k_polyrizon.htm (6-K) — 10KB
- ea026929302ex99-1_polyrizon.htm (EX-99.1) — 14KB
- 0001213900-25-120363.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: December 11, 2025 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 3